JLE

e-VEGF-IMMUNO-actu

MENU

Les anti-angiogéniques bientôt en traitement adjuvant ? Volume 12, issue 1, Mars 2017

Figures






Author
1 Université de Bordeaux, Inserm U1218, France

Wu et al. Efficacy of cotargeting angiopoietin-2 and the VEGF pathway in the adjuvant postsurgical setting for early breast, colorectal, and renal cancers. Cancer Research 2016; 76: 6988-7000.